NASDAQ:ANIKAnika Therapeutics Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Anika Therapeutics Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $34.47 +0.91 (+2.71 %) (As of 08/7/2020 04:00 PM ET) Add Compare Share Today's Range$33.70Now: $34.47▼$35.2050-Day Range$33.01MA: $35.74▼$38.5752-Week Range$22.01Now: $34.47▼$75.71Volume117,018 shsAverage Volume112,332 shsMarket Capitalization$489.47 millionP/E Ratio55.60Dividend YieldN/ABeta1.12 ProfileAnalyst RatingsAdvanced ChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media Anika Therapeutics, Inc., together with its subsidiaries, provides orthopedic medicines for patients with degenerative orthopedic diseases and traumatic conditions in the United States and internationally. The company develops, manufactures, and commercializes therapeutic products based on its proprietary hyaluronic acid (HA) technology. Its orthobiologics products comprise ORTHOVISC, ORTHOVISC mini, MONOVISC, and CINGAL for the treatment of osteoarthritis of the knee; HYALOFAST, a biodegradable support for human bone marrow mesenchymal stem cells used for cartilage regeneration and as an adjunct for microfracture surgery; HYALONECT, a resorbable knitted fabric mesh; HYALOSS MATRIX, HYAFF fibers used to mix blood/bone grafts to form a paste for bone regeneration; and HYALOGLIDE, an ACP gel used in tenolysis treatment. The company's dermal products include wound care products that comprise HYALOMATRIX and HYALOFILL for the treatment of complex wounds, such as burns and ulcers, and for use in connection with the regeneration of skin; and ELEVESS, an aesthetic dermatology product. Its surgical products comprise HYALOBARRIER, a post-operative adhesion barrier for use in the abdomino-pelvic area; MEROGEL, a woven fleece nasal packing; and MEROGEL INJECTABLE, a viscous hydrogel. The company also offers ophthalmic products, including injectable HA products that are used as viscoelastic agents in ophthalmic surgical procedures, such as cataract extraction and intraocular lens implantation; and veterinary products, which include HYVISC, an injectable HA product for the treatment of joint dysfunction in horses. The company was founded in 1983 and is headquartered in Bedford, Massachusetts.Read More Beat the Market (BTM) Rank™ 3.3 Analyst's Opinion Consensus RatingAnika Therapeutics has received a consensus rating of Buy. The company's average rating score is 2.50, and is based on 1 buy rating, 1 hold rating, and 1 sell rating.Price Target Upside/DownsideAccording to analysts' consensus price target of $53.75, Anika Therapeutics has a potential upside of 55.9% from its current price of $34.47.Amount of Analyst CoverageAnika Therapeutics has received no research coverage in the past 90 days. Previous Next 2.5 Community Rank Outperform VotesAnika Therapeutics has received 286 “outperform” votes. (Add your “outperform” vote.)Underperform VotesAnika Therapeutics has received 286 “underperform” votes. (Add your “underperform” vote.)Community SentimentAnika Therapeutics has received 50.00% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Anika Therapeutics and other stocks. Vote “Outperform” if you believe ANIK will outperform the S&P 500 over the long term. Vote “Underperform” if you believe ANIK will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldAnika Therapeutics does not currently pay a dividend.Dividend GrowthAnika Therapeutics does not have a long track record of dividend growth. Previous Next 1.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Anika Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $43,727.00 in company stock.Percentage Held by InsidersOnly 2.53% of the stock of Anika Therapeutics is held by insiders.Percentage Held by Institutions91.99% of the stock of Anika Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 1.9 Earnings and Valuation Earnings GrowthEarnings for Anika Therapeutics are expected to grow by 53.41% in the coming year, from $0.88 to $1.35 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Anika Therapeutics is 55.60, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 15.84.Price to Earnings Ratio vs. SectorThe P/E ratio of Anika Therapeutics is 55.60, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 20.09.Price to Earnings Growth RatioAnika Therapeutics has a PEG Ratio of 3.92. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioAnika Therapeutics has a P/B Ratio of 1.71. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next Analyst Opinion: 3.3Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 1.9 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.73 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Surgical & medical instruments Sub-IndustryHealth Care Supplies SectorMedical Current SymbolNASDAQ:ANIK Previous Symbol CUSIP03525510 CIK898437 Webwww.anikatherapeutics.com Phone781-457-9000Debt Debt-to-Equity Ratio0.25 Current Ratio7.93 Quick Ratio6.26Price-To-Earnings Trailing P/E Ratio55.60 Forward P/E Ratio39.17 P/E Growth3.92 Sales & Book Value Annual Sales$114.51 million Price / Sales4.27 Cash Flow$2.51 per share Price / Cash Flow13.74 Book Value$20.21 per share Price / Book1.71Profitability EPS (Most Recent Fiscal Year)$2.05 Net Income$27.19 million Net Margins7.17% Return on Equity8.05% Return on Assets6.23%Miscellaneous Employees133 Outstanding Shares14,200,000Market Cap$489.47 million Next Earnings Date10/22/2020 (Estimated) OptionableOptionable $34.47 +0.91 (+2.71 %) (As of 08/7/2020 04:00 PM ET) 30 days | 90 days | 365 days | Advanced Chart Receive ANIK News and Ratings via Email Sign-up to receive the latest news and ratings for ANIK and its competitors with MarketBeat's FREE daily newsletter. Anika Therapeutics (NASDAQ:ANIK) Frequently Asked Questions How has Anika Therapeutics' stock been impacted by COVID-19 (Coronavirus)? Anika Therapeutics' stock was trading at $36.39 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, ANIK stock has decreased by 5.3% and is now trading at $34.47. View which stocks have been most impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of Anika Therapeutics? 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Anika Therapeutics in the last year. There are currently 1 sell rating, 1 hold rating, 1 buy rating and 1 strong buy rating for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Anika Therapeutics. When is Anika Therapeutics' next earnings date? Anika Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, October 22nd 2020. View our earnings forecast for Anika Therapeutics. How were Anika Therapeutics' earnings last quarter? Anika Therapeutics Inc (NASDAQ:ANIK) released its quarterly earnings data on Thursday, July, 30th. The biotechnology company reported ($0.54) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.21) by $0.33. The biotechnology company earned $30.68 million during the quarter, compared to the consensus estimate of $16.73 million. Anika Therapeutics had a return on equity of 8.05% and a net margin of 7.17%. View Anika Therapeutics' earnings history. What price target have analysts set for ANIK? 4 Wall Street analysts have issued twelve-month price objectives for Anika Therapeutics' shares. Their forecasts range from $29.00 to $65.00. On average, they anticipate Anika Therapeutics' stock price to reach $53.75 in the next year. This suggests a possible upside of 55.9% from the stock's current price. View analysts' price targets for Anika Therapeutics. Has Anika Therapeutics been receiving favorable news coverage? News stories about ANIK stock have trended negative on Monday, InfoTrie Sentiment reports. The research firm rates the sentiment of media coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Anika Therapeutics earned a media sentiment score of -2.0 on InfoTrie's scale. They also assigned press coverage about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the stock's share price in the next several days. View the latest news about Anika Therapeutics. Who are some of Anika Therapeutics' key competitors? Some companies that are related to Anika Therapeutics include Align Technology (ALGN), West Pharmaceutical Services (WST), Cooper Companies (COO), Quidel (QDEL), DENTSPLY SIRONA (XRAY), Neogen (NEOG), Haemonetics (HAE), ICU Medical (ICUI), Merit Medical Systems (MMSI), STAAR Surgical (STAA), Atrion (ATRI), Cerus (CERS), OraSure Technologies (OSUR), Meridian Bioscience (VIVO) and Antares Pharma (ATRS). View all competitors. What other stocks do shareholders of Anika Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Anika Therapeutics investors own include Alibaba Group (BABA), Gilead Sciences (GILD), Broadcom (AVGO), CVS Health (CVS), Celgene (CELG), Walt Disney (DIS), Enterprise Products Partners (EPD), NVIDIA (NVDA), Skyworks Solutions (SWKS) and AT&T (T). Who are Anika Therapeutics' key executives? Anika Therapeutics' management team includes the following people: Mr. Joseph G. Darling, CEO, Pres & Director (Age 61)Ms. Sylvia Cheung, CFO, Treasurer & Sec. (Age 44)Dr. Edward S. Ahn, Chief Technology & Strategy Officer (Age 47)Mr. Thomas M. Finnerty, Chief HR Officer (Age 61)Mr. Alexei Goraltchouk, VP of Operations What is Anika Therapeutics' stock symbol? Anika Therapeutics trades on the NASDAQ under the ticker symbol "ANIK." Who are Anika Therapeutics' major shareholders? Anika Therapeutics' stock is owned by many different retail and institutional investors. Top institutional investors include Boston Trust Walden Corp (2.52%), Capital Management Corp VA (1.26%), Principal Financial Group Inc. (0.85%), Russell Investments Group Ltd. (0.76%), Foundry Partners LLC (0.53%) and Zweig DiMenna Associates LLC (0.43%). Company insiders that own Anika Therapeutics stock include Glenn R Larsen, James Loerop, Jeffery S Thompson, Joseph G Darling, Joseph L Bower, Raymond J Land and Sylvia Cheung. View institutional ownership trends for Anika Therapeutics. Which institutional investors are selling Anika Therapeutics stock? ANIK stock was sold by a variety of institutional investors in the last quarter, including 6 Meridian, UBS Group AG, Fisher Asset Management LLC, PNC Financial Services Group Inc., State Board of Administration of Florida Retirement System, and Texas Permanent School Fund. Company insiders that have sold Anika Therapeutics company stock in the last year include Glenn R Larsen, James Loerop, Joseph L Bower, Raymond J Land, and Sylvia Cheung. View insider buying and selling activity for Anika Therapeutics. Which institutional investors are buying Anika Therapeutics stock? ANIK stock was purchased by a variety of institutional investors in the last quarter, including Capital Management Corp VA, Zweig DiMenna Associates LLC, Russell Investments Group Ltd., Boston Trust Walden Corp, Foundry Partners LLC, Brookstone Capital Management, Diversified Trust Co, and Rafferty Asset Management LLC. View insider buying and selling activity for Anika Therapeutics. How do I buy shares of Anika Therapeutics? Shares of ANIK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Anika Therapeutics' stock price today? One share of ANIK stock can currently be purchased for approximately $34.47. How big of a company is Anika Therapeutics? Anika Therapeutics has a market capitalization of $489.47 million and generates $114.51 million in revenue each year. The biotechnology company earns $27.19 million in net income (profit) each year or $2.05 on an earnings per share basis. Anika Therapeutics employs 133 workers across the globe. What is Anika Therapeutics' official website? The official website for Anika Therapeutics is www.anikatherapeutics.com. How can I contact Anika Therapeutics? Anika Therapeutics' mailing address is 32 WIGGINS AVENUE, BEDFORD MA, 01730. The biotechnology company can be reached via phone at 781-457-9000 or via email at [email protected] This page was last updated on 8/10/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
